Metraipolis › archive › dc_3cf89b7e8de2
A real-world observational study of second-line anti-TNFα treatment in patients with ulcerative colitis who received vedolizumab as a first-line biologic — Europe PMC PMID:42222351
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42222351
- DOI
- 10.1093/crocol/otag042
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T13:42:26.262Z
- SHA-256 of the archived text
9465ec0a0d1d287f11ccc82c87d46b986b26989a5ee1f391fc379c65ce0d2b6b- Stable URL of this page
https://metraipolis.com/documento/dc_3cf89b7e8de2
How to cite
A real-world observational study of second-line anti-TNFα treatment in patients with ulcerative colitis who received vedolizumab as a first-line biologic — Europe PMC PMID:42222351 — Europe PMC (en), https://europepmc.org/article/MED/42222351 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3cf89b7e8de2 (Metraipolis archive dc_3cf89b7e8de2, sha256 9465ec0a0d1d287f11ccc82c87d46b986b26989a5ee1f391fc379c65ce0d2b6b)
BibTeX
@misc{dc3cf89b7e8de2,
title = {A real-world observational study of second-line anti-TNFα treatment in patients with ulcerative colitis who received vedolizumab as a first-line biologic — Europe PMC PMID:42222351},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42222351},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3cf89b7e8de2; sha256 9465ec0a0d1d287f11ccc82c87d46b986b26989a5ee1f391fc379c65ce0d2b6b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42222351. Agents can read the archived copy with the MCP tool read_document.